Mineralys Therapeutics Inc
MLYS13.050USD
-0.615-4.50%
Market hours （ET）Quotes delayed by 15 min
USD0.000Pre-market (ET)
846.63MMarket Cap
LossP/E TTM
Mineralys Therapeutics Inc
13.050
-0.615-4.50%
Quarterly
Quarterly+Annual
Quarterly
Annual
YOY
Hide blank rows
FY2025Q1
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022Q4
FY2022Q2
FY2022Q1
FY2021Q4
Operating expenses
25.69%44.45M
86.81%51.77M
128.77%60.11M
187.05%45.17M
136.73%35.36M
176.89%27.71M
--26.27M
142.86%15.73M
97.36%14.94M
41.30%10.01M
--6.48M
--7.57M
--7.08M
R&D expenses
23.17%37.88M
88.17%44.57M
139.94%53.98M
230.47%39.27M
150.17%30.75M
202.95%23.68M
--22.50M
112.40%11.88M
81.37%12.29M
18.17%7.82M
--5.59M
--6.78M
--6.62M
Depreciation, depletion, and amortization
87.50%15.00K
--15.00K
--11.00K
--9.00K
--8.00K
--0.00
--0.00
--0.00
--0.00
----
----
----
----
Operating profit
-25.69%-44.45M
-86.81%-51.77M
-128.77%-60.11M
-187.05%-45.17M
-136.73%-35.36M
-176.89%-27.71M
---26.27M
-142.86%-15.73M
-97.36%-14.94M
-41.30%-10.01M
---6.48M
---7.57M
---7.08M
Net non-operating interest income (expenses)
Non-operating interest income
-41.89%2.24M
-15.42%2.81M
7.43%3.77M
15.56%4.15M
65.44%3.85M
--3.32M
--3.51M
--3.59M
--2.33M
----
----
----
----
Non-operating interest expense
----
----
----
----
----
----
----
----
----
----
----
----
--0.00
Special income (expenses)
----
----
----
----
----
----
----
----
----
--0.00
----
----
--0.00
Other non-operating income (expenses)
-400.00%-3.00K
1100.00%12.00K
---10.00K
100.00%2.00K
0.00%1.00K
--1.00K
--0.00
--1.00K
--1.00K
--0.00
--0.00
--0.00
--0.00
Income before tax
-33.97%-42.21M
-100.69%-48.95M
-147.55%-56.34M
-237.81%-41.01M
-149.90%-31.51M
-168.81%-24.39M
---22.76M
-87.39%-12.14M
-66.57%-12.61M
-28.10%-9.07M
---6.48M
---7.57M
---7.08M
Income after tax
-33.97%-42.21M
-100.69%-48.95M
-147.55%-56.34M
-237.81%-41.01M
-149.90%-31.51M
-168.81%-24.39M
---22.76M
-87.39%-12.14M
-66.57%-12.61M
-28.10%-9.07M
---6.48M
---7.57M
---7.08M
Net income from continuous operations
-33.97%-42.21M
-100.69%-48.95M
-147.55%-56.34M
-237.81%-41.01M
-149.90%-31.51M
-168.81%-24.39M
---22.76M
-87.39%-12.14M
-66.57%-12.61M
-28.10%-9.07M
---6.48M
---7.57M
---7.08M
Net income attributable to controlling interests
-33.97%-42.21M
-100.69%-48.95M
-147.55%-56.34M
-237.81%-41.01M
-149.90%-31.51M
-168.81%-24.39M
---22.76M
-87.39%-12.14M
-66.57%-12.61M
-28.10%-9.07M
---6.48M
---7.57M
---7.08M
Net income attributable to common shareholders
-33.97%-42.21M
-100.69%-48.95M
-147.55%-56.34M
-237.81%-41.01M
-149.90%-31.51M
-168.81%-24.39M
---22.76M
-87.39%-12.14M
-66.57%-12.61M
-28.10%-9.07M
---6.48M
---7.57M
---7.08M
Basic earnings per share
-13.15%-0.79
-61.20%-0.98
-98.43%-1.13
-172.10%-0.83
-127.40%-0.70
-148.19%-0.61
---0.57
75.71%-0.31
-51.08%-0.31
-28.09%-0.24
---1.26
---0.20
---0.19
Diluted earnings per share
-13.15%-0.79
-61.20%-0.98
-98.43%-1.13
-172.10%-0.83
-127.40%-0.70
-148.19%-0.61
---0.57
75.71%-0.31
-51.08%-0.31
-28.09%-0.24
---1.26
---0.20
---0.19
Dividend per share
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
Currency unit
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
Audit opinions
--
--
--
--
--
--
--
--
--
--
--
--
--
